October 2021 in “Dermatology Reports” This study found that serum IL-17A levels were significantly higher in patients with alopecia areata compared to healthy controls and correlated with disease severity and activity.
June 2023 in “Benha Journal of Applied Sciences” This review concluded that interleukin-17 is involved in the development of female-pattern baldness, suggesting a potential inflammatory role in the condition’s underlying causes.
December 2024 in “Kufa Medical journal” The study reported that patients with alopecia areata had significantly higher serum levels of IL-17A and IL-2 compared to healthy controls, suggesting these interleukins may play an important role in the disease, though they did not correlate with its severity or duration.
April 2023 in “The Egyptian Journal of Hospital Medicine” This case control study investigated serum IL-17A levels in alopecia areata patients compared to healthy controls to explore its potential role in the disease's pathogenesis.
September 2025 in “Diseases” This study found that patients with patchy alopecia areata had significantly higher serum levels of pro-inflammatory cytokines IL-6, TNF-α, IL-17A, and IL-21 compared to healthy controls, with these levels correlating positively with disease severity, age, and disease duration.